期刊
ACS CHEMICAL NEUROSCIENCE
卷 10, 期 3, 页码 1765-1782出版社
AMER CHEMICAL SOC
DOI: 10.1021/acschemneuro.8b00648
关键词
chemical probes; dual inhibitors; PDES inhibition; class I HDAC selective inhibition; Alzheimer's disease; in vivo test
资金
- Foundation for Applied Medical Research, University of Navarra (Pamplona, Spain)
- Ministerio de Economia y Competitividad [FIS PI12/00710]
- FSE (Inncorpora-Torres Quevedo grant) [PTQ-12-05641, PTQ-14-07320]
- FIS projects [11/02861, 14/01244]
In order to determine the contributions of histone deacetylase (HDAC) isoforms to the beneficial effects of dual phosphodiesterase 5 (PDES) and pan-HDAC inhibitors on in vivo models of Alzheimer's disease (AD), we have designed, synthesized, and tested novel chemical probes with the desired target compound profile of PDES and class I HDAC selective inhibitors. Compared to previous hydroxamate-based series, these molecules exhibit longer residence times on HDACs. In this scenario, shorter or longer preincubation times may have a significant impact on the IC50 values of these compounds and therefore on their corresponding selectivity profiles on the different HDAC isoforms. On the other hand, different chemical series have been explored and, as expected, some pairwise comparisons show a clear impact of the scaffold on biological responses (e.g., 35a vs 40a). The lead identification process led to compound 29a, which shows an adequate ADME-Tox profile and in vivo target engagement (histone acetylation and cAMP/cGMP response element-binding (CREB) phosphorylation) in the central nervous system (CNS), suggesting that this compound represents an optimized chemical probe; thus, 29a has been assayed in a mouse model of AD (Tg2576).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据